Proto-oncogene products as target antigens for cancer vaccines (review)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Enthusiasm for cancer vaccines has undoubtedly been fueled by the success of vaccines against infectious diseases. The underlying principle of antibacterial or antiviral vaccines is the induction of an immune response to foreign (non-self) antigen(s) encoded by the invading microorganism. Until recently, the premise of a response to non-self antigen would have seemed the sine qua non of any vaccine, so self evident as to scarcely merit remark. In fact, the vaccine concept discussed here eschews this premise in favor of a response to self antigen as an anti-tumor modality. Vaccination would target proteins encoded by proto-oncogenes. As measured relative to their expression in normal cells, proto-oncogene-encoded proteins are overexpressed in the tumor cells of a number of human cancers. Any vaccine intended to target self antigen must manage to both circumvent a possible tolerogenicity of the antigen and, at the same time, avoid the induction of autoimmune pathology. For the vaccine concept discussed here, the difference in levels of proto- oncogene expression between tumor cells and normal cells provides a basis for satisfying both of these requirements and hence a basis for the immune- mediated destruction of tumor tissue.

Original languageEnglish (US)
Pages (from-to)863-868
Number of pages6
JournalInternational Journal of Oncology
Volume11
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Cancer Vaccines
Proto-Oncogenes
Oncogene Proteins
Vaccines
Antigens
Proto-Oncogene Proteins
Autoantigens
Neoplasms
Antiviral Agents
Communicable Diseases
Vaccination
Cell Count
Pathology

Keywords

  • Cancer vaccines
  • Proto-oncogenes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Proto-oncogene products as target antigens for cancer vaccines (review). / Halpern, Michael.

In: International Journal of Oncology, Vol. 11, No. 4, 1997, p. 863-868.

Research output: Contribution to journalArticle

@article{d572b95616fc4aaca8acd045d7fa6962,
title = "Proto-oncogene products as target antigens for cancer vaccines (review)",
abstract = "Enthusiasm for cancer vaccines has undoubtedly been fueled by the success of vaccines against infectious diseases. The underlying principle of antibacterial or antiviral vaccines is the induction of an immune response to foreign (non-self) antigen(s) encoded by the invading microorganism. Until recently, the premise of a response to non-self antigen would have seemed the sine qua non of any vaccine, so self evident as to scarcely merit remark. In fact, the vaccine concept discussed here eschews this premise in favor of a response to self antigen as an anti-tumor modality. Vaccination would target proteins encoded by proto-oncogenes. As measured relative to their expression in normal cells, proto-oncogene-encoded proteins are overexpressed in the tumor cells of a number of human cancers. Any vaccine intended to target self antigen must manage to both circumvent a possible tolerogenicity of the antigen and, at the same time, avoid the induction of autoimmune pathology. For the vaccine concept discussed here, the difference in levels of proto- oncogene expression between tumor cells and normal cells provides a basis for satisfying both of these requirements and hence a basis for the immune- mediated destruction of tumor tissue.",
keywords = "Cancer vaccines, Proto-oncogenes",
author = "Michael Halpern",
year = "1997",
language = "English (US)",
volume = "11",
pages = "863--868",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Proto-oncogene products as target antigens for cancer vaccines (review)

AU - Halpern, Michael

PY - 1997

Y1 - 1997

N2 - Enthusiasm for cancer vaccines has undoubtedly been fueled by the success of vaccines against infectious diseases. The underlying principle of antibacterial or antiviral vaccines is the induction of an immune response to foreign (non-self) antigen(s) encoded by the invading microorganism. Until recently, the premise of a response to non-self antigen would have seemed the sine qua non of any vaccine, so self evident as to scarcely merit remark. In fact, the vaccine concept discussed here eschews this premise in favor of a response to self antigen as an anti-tumor modality. Vaccination would target proteins encoded by proto-oncogenes. As measured relative to their expression in normal cells, proto-oncogene-encoded proteins are overexpressed in the tumor cells of a number of human cancers. Any vaccine intended to target self antigen must manage to both circumvent a possible tolerogenicity of the antigen and, at the same time, avoid the induction of autoimmune pathology. For the vaccine concept discussed here, the difference in levels of proto- oncogene expression between tumor cells and normal cells provides a basis for satisfying both of these requirements and hence a basis for the immune- mediated destruction of tumor tissue.

AB - Enthusiasm for cancer vaccines has undoubtedly been fueled by the success of vaccines against infectious diseases. The underlying principle of antibacterial or antiviral vaccines is the induction of an immune response to foreign (non-self) antigen(s) encoded by the invading microorganism. Until recently, the premise of a response to non-self antigen would have seemed the sine qua non of any vaccine, so self evident as to scarcely merit remark. In fact, the vaccine concept discussed here eschews this premise in favor of a response to self antigen as an anti-tumor modality. Vaccination would target proteins encoded by proto-oncogenes. As measured relative to their expression in normal cells, proto-oncogene-encoded proteins are overexpressed in the tumor cells of a number of human cancers. Any vaccine intended to target self antigen must manage to both circumvent a possible tolerogenicity of the antigen and, at the same time, avoid the induction of autoimmune pathology. For the vaccine concept discussed here, the difference in levels of proto- oncogene expression between tumor cells and normal cells provides a basis for satisfying both of these requirements and hence a basis for the immune- mediated destruction of tumor tissue.

KW - Cancer vaccines

KW - Proto-oncogenes

UR - http://www.scopus.com/inward/record.url?scp=0030987664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030987664&partnerID=8YFLogxK

M3 - Article

C2 - 21528286

AN - SCOPUS:0030987664

VL - 11

SP - 863

EP - 868

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -